Clinical trial · Observational
APOLLO(Aromatase Inhibitor Patient cOmpLiance Program With qoL Questionaire)
A Prospective Observational Study of Compliance in the Patients Receiving Aromatase Inhibitor as an Adjuvant Therapy in Postmenopausal Early Breast Cancer
NCT00523315CI-TRIAL-00004896APOLLOcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To describe patients' compliance of taking Aromatase Inhibitor as an adjuvant treatment in the postmenopausal, early breast cancer as seen under current practice
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Provision of written informed consent * Patients with early breast cancer who are scheduled to receive first-line adjuvant endocrine therapy with aromatase inhibitor under the routine clinical practice * Histologically or cytologically proven to be HR+(ER or PR +) * Postmenopausal woman, defined as a woman fulfilling any of the following criteria(by the local guideline): * Age \>= 50 years * Age \< 50 years with amenorrhoea \> 12 months and an intact uterus * FSH levels within postmenopausal range (over 30-40 IU/ml), or * Having undergone a bilateral oophorectomy. * No other concomitant endocrine therapy such as estrogen therapy or selective estrogen receptor modulators Exclusion Criteria: * Recurrence of breast cancer * Known hypersensitivity to aromatase inhibitor or to any of the excipients * Any severe concomitant condition which makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the trial protocol * Previous inclusion in the present study * Participation in a clinical study during the last 30 days
References
Publications (0)
Data not yet available
No reference posted for this study.